| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-05-18 08:46:24 UTC |
|---|
| Update Date | 2022-09-22 17:43:47 UTC |
|---|
| HMDB ID | HMDB0001930 |
|---|
| Secondary Accession Numbers | - HMDB0005003
- HMDB01930
- HMDB05003
|
|---|
| Metabolite Identification |
|---|
| Common Name | Ranitidine |
|---|
| Description | Ranitidine (CAS: 66357-35-5) is a non-imidazole blocker of histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers (PubChem). Ranitidine is a histamine H2-receptor antagonist that inhibits stomach acid production and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It is currently marketed by GlaxoSmithKline under the trade name Zantac (Wikipedia ). |
|---|
| Structure | CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+ |
|---|
| Synonyms | | Value | Source |
|---|
| Ranitidina | ChEBI | | Ranitidinum | ChEBI | | 2-(Benzhydryloxy)-N,N-dimethylethylamine | HMDB | | 2-Diphenylmethoxy-N,N-demthylethanamine | HMDB | | alpha-(2-Dimethylaminoethoxy)diphenylmethane | HMDB | | beta-Dimethylaminoethanol diphenylmethyl ether | HMDB | | beta-Dimethylaminoethyl benzhydryl ether | HMDB | | Difenhidramina | HMDB | | Diphenhydraminum | HMDB | | N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine | HMDB | | O-Benzhydryldimethylaminoethanol | HMDB | | Restamin | HMDB | | a-(2-Dimethylaminoethoxy)diphenylmethane | HMDB | | Α-(2-dimethylaminoethoxy)diphenylmethane | HMDB | | b-Dimethylaminoethanol diphenylmethyl ether | HMDB | | Β-dimethylaminoethanol diphenylmethyl ether | HMDB | | b-Dimethylaminoethyl benzhydryl ether | HMDB | | Β-dimethylaminoethyl benzhydryl ether | HMDB | | Benadryl | HMDB | | Dobacen | HMDB | | Bendylate | HMDB | | Dimedrolum | HMDB | | Alledryl | HMDB | | Allergan | HMDB | | Allergina | HMDB | | Benzantin | HMDB | | Difenhydramine | HMDB | | Dimedrol | HMDB | | Dimethylamine benzhydryl ester | HMDB | | Diphamine | HMDB | | Diphantine | HMDB | | Allerdryl | HMDB | | Benzhydramine | HMDB | | Benhydramin | HMDB | | Diphenhydramine citrate (1:1) | HMDB | | Diphenylhydramine | HMDB | | 2-Diphenylmethoxy-N,N-dimethylethylamine | HMDB | | Benylin | HMDB | | Diphenylhydramin | HMDB | | Citrate, diphenhydramine | HMDB | | Diphenhydramine citrate | HMDB | | Diphenhydramine hydrochloride | HMDB | | Dormin | HMDB | | Hydrochloride, diphenhydramine | HMDB | | Achedos | HMDB | | Acidex | HMDB | | Atural | HMDB | | Axoban | HMDB | | Coralen | HMDB | | Curan | HMDB | | Duractin | HMDB | | Ezopta | HMDB | | Gastrial | HMDB | | Gastrosedol | HMDB | | Istomar | HMDB | | Logast | HMDB | | Mauran | HMDB | | Microtid | HMDB | | Ptinolin | HMDB | | Quantor | HMDB | | Quicran | HMDB | | Radinat | HMDB | | Randin | HMDB | | Ranidine | HMDB | | Ranin | HMDB | | Raniogas | HMDB | | Ranisen | HMDB | | Raniter | HMDB | | Ranitidine (form I and form II) | HMDB | | Ranitidine base | HMDB | | Ranitidine HCL 1/2 type | HMDB | | Ranitiget | HMDB | | Rantacid | HMDB | | Rantidine | HMDB | | Ratic | HMDB | | Raticina | HMDB | | RND | HMDB | | Sampep | HMDB | | Taural | HMDB | | Ul-pep | HMDB | | Ulceranin | HMDB | | Urantac | HMDB | | Verlost | HMDB | | Vesyca | HMDB | | Vizerul | HMDB | | Weichilin | HMDB | | Weidos | HMDB | | Xanidine | HMDB | | Zantab | HMDB | | ZANTAC | HMDB | | Zantadin | HMDB | | Hydrochloride, ranitidine | HMDB | | Ranitidin | HMDB | | Biotidin | HMDB | | Ranitidine hydrochloride | HMDB | | Sostril | HMDB | | N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine | HMDB | | Zantic | HMDB | | (e)-Ranitidine | HMDB | | Ranitidine | HMDB |
|
|---|
| Chemical Formula | C13H22N4O3S |
|---|
| Average Molecular Weight | 314.404 |
|---|
| Monoisotopic Molecular Weight | 314.14126128 |
|---|
| IUPAC Name | dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine |
|---|
| Traditional Name | ranitidine |
|---|
| CAS Registry Number | 82530-72-1 |
|---|
| SMILES | CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O |
|---|
| InChI Identifier | InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+ |
|---|
| InChI Key | VMXUWOKSQNHOCA-UKTHLTGXSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic nitrogen compounds |
|---|
| Class | Organonitrogen compounds |
|---|
| Sub Class | Amines |
|---|
| Direct Parent | Aralkylamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Aralkylamine
- Furan
- Heteroaromatic compound
- C-nitro compound
- Tertiary amine
- Tertiary aliphatic amine
- Organic nitro compound
- Secondary aliphatic amine
- Organic oxoazanium
- Secondary amine
- Thioether
- Sulfenyl compound
- Allyl-type 1,3-dipolar organic compound
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Oxacycle
- Organoheterocyclic compound
- Dialkylthioether
- Organic zwitterion
- Organooxygen compound
- Organosulfur compound
- Organic oxygen compound
- Organic oxide
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 1.93 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.65 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.8903 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.39 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 177.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 343.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 233.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 64.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 175.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 53.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 305.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 313.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 1141.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 667.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 49.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 582.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 186.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 231.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 937.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 796.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 236.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Ranitidine,1TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)O1 | 2760.9 | Semi standard non polar | 33892256 | | Ranitidine,1TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)O1 | 2499.7 | Standard non polar | 33892256 | | Ranitidine,1TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)O1 | 3560.8 | Standard polar | 33892256 | | Ranitidine,1TMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C | 2728.2 | Semi standard non polar | 33892256 | | Ranitidine,1TMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C | 2522.0 | Standard non polar | 33892256 | | Ranitidine,1TMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C | 3619.3 | Standard polar | 33892256 | | Ranitidine,2TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)[Si](C)(C)C)O1 | 2684.6 | Semi standard non polar | 33892256 | | Ranitidine,2TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)[Si](C)(C)C)O1 | 2683.7 | Standard non polar | 33892256 | | Ranitidine,2TMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C)[Si](C)(C)C)O1 | 3102.2 | Standard polar | 33892256 | | Ranitidine,1TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)O1 | 2941.6 | Semi standard non polar | 33892256 | | Ranitidine,1TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)O1 | 2722.7 | Standard non polar | 33892256 | | Ranitidine,1TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)O1 | 3574.5 | Standard polar | 33892256 | | Ranitidine,1TBDMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C(C)(C)C | 2921.5 | Semi standard non polar | 33892256 | | Ranitidine,1TBDMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C(C)(C)C | 2735.0 | Standard non polar | 33892256 | | Ranitidine,1TBDMS,isomer #2 | CN/C(=C\[N+](=O)[O-])N(CCSCC1=CC=C(CN(C)C)O1)[Si](C)(C)C(C)(C)C | 3604.8 | Standard polar | 33892256 | | Ranitidine,2TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)O1 | 3099.3 | Semi standard non polar | 33892256 | | Ranitidine,2TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)O1 | 3006.0 | Standard non polar | 33892256 | | Ranitidine,2TBDMS,isomer #1 | CN(C)CC1=CC=C(CSCCN(/C(=C/[N+](=O)[O-])N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)O1 | 3217.8 | Standard polar | 33892256 |
|
|---|
| General References | - Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
|---|